BioSpace News Archive

A paper demonstrating Spheryx’s xSight’s ability to provide new insights into complex particles has been published in the journal Soft Matter.

Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the appointment of Richard Scheller, Ph.D., and Thomas Südhof, M.D., as co-chairs of the Company’s Strategic Portfolio Advice and Review Committee (SPARC).

Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 3,000 shares of Pulse Biosciences common stock to a recently hired non-executive employee under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on December 16, 2019.

Puma Biotechnology, Inc. announced that on November 1, 2019 and December 2, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 42,875 shares of Puma common stock to five new non-executive employees and an aggregate of 81,750 shares of Puma common stock to fifteen new non-executive employees, respectively.

OWC Pharmaceutical Research Corp., represented by its wholly-owned subsidiary, One World Cannabis Ltd. announced that, on December 9, 2019, the United States Patent and Trademark Office issued a Notice of Allowance indicating that OWC Israel’s Patent Application No. 15/629,230 directed to cannabis based extracts and topical formulations for use in skin disorders, is allowed for issuance as a patent.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming 38th Annual JP Morgan Healthcare Conference in San Francisco.

Tabula Rasa HealthCare®, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, continues its market penetration in PACE (Programs of All-inclusive Care for the Elderly).

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced an agreement by its subsidiary Belgian Volition SPRL to acquire an epigenetic reagent company, Octamer GmbH (“Octamer”), for approximately $725,000 consisting of cash and shares of restricted common stock of Volition.

Accomplished executive brings business development, alliance management and commercial leadership expertise based on over 20 years in the biopharmaceutical industry

vybe urgent care, the leading independent operator of urgent care centers in the Greater Philadelphia area, announces the opening of two new centers in Northeast Philadelphia and Bensalem, PA.